New advances in stroke prevention in atrial fibrillation: Ximelagatran and direct thrombin inhibition

European Heart Journal, Supplement

Volumn 6, Issue B, 2004, Pages

  Olsson, S Bertil ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Non valvular atrial fibrillation; Oral direct thrombin inhibitors; Oral vitamin K antagonists; SPORTIF III; Stroke Prevention; Ximelagatran

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; MELAGATRAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG CROSS REACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; THROMBOEMBOLISM; THROMBOSIS;

EID: 1942488996     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehjsup.2004.01.014     Document Type: Review

References (24)

1. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
2. Feinberg WM, Blackshear JL, Laupacis A et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-73.
3. Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-8.
5. Penado S, Cano M, Acha O et al. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med 2003;114:206-10.
6. Petersen P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-9.
7. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Engl J Med 1990;323:1505-11.
8. Connolly SJ, Laupacis A, Gent M et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
9. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-39.
10. Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406-12.
11. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-62.
12. Hart RG, Benavente O, McBride R et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
13. Hylek EM, Skates SJ, Sheehan MA et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
14. Gustafsson D, Nystrom J, Carlsson S et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376795: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101:171-81.
15. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003;109(Suppl 1):S9-S15.
16. Wells PS, Holbrook AM, Crowther NR et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-83.
17. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003;41:1445-51.
18. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-8.
19. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-98.
20. Casey M, Hanley K. A measurement of the efficacy of anticoagulation monitoring in a general practice based setting. Ir Med J 2001;94:245-6.
21. Huisman MV and on behalf of the THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran for acute deep vein thrombosis with or without pulmonary embolism. In: XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, UK, July 12-18, 2003; Abstract OC003.
22. Schulman S, Wahlander K, Lundstrom T et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-21.
23. Wallentin L, Wilcox RG, Weaver WD et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-97.
24. Van Aken H, Bode C, Darius H et al. Anticoagulation: the present and future. Clin Appl Thromb Hemost 2001;7:195-204.